Nectar Lifesciences
BSE: 532649 | NSE: NECLIFE | ISIN: INE023H01027 | SECTOR: Biotechnology & DrugsOpen
34.60High
34.60Low
34.15Prev Close
34.53P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
7.71BVolume
6.25KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
34.32Ask
34.43
Promoter Pledge Holding - 44.35%
Promoter Name | No of Shares | Percentage |
---|---|---|
SANJIV GOYAL | 5,58,45,600 | 31.33% |
SANJIV (HUF) | 4,36,22,400 | 24.47% |
Company Description
- Biotechnology & Drugs
BSE
532649NSE
NECLIFEISIN
INE023H01027
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Company Officers
Sanjiv Goyal
Executive Chairman of the Board, Managing DirectorAmit Chadah
Chief Executive OfficerSushil Kapoor
Chief Financial OfficerNeha Vaishnav
Chief Compliance Officer, Company SecretaryPuneet Sud
Additional Director, Wholetime Director - Operations